ADVANCED DRUG DELIVERY REVIEWS先进药物递送评论
ADVANCED DRUG DELIVERY REVIEWS(英文缩写 ADV DRUG DELIVER REV),ISSN 0169-409X,eISSN 1872-8294,中文译名:先进药物递送评论 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 17.873 | Q1 |
| 2022 | 16.100 | Q1 |
| 2023 | 15.200 | Q1 |
| 2024 | 17.600 | Q1 |
| 2025 | 21.000 | Q1 |
ADVANCED DRUG DELIVERY REVIEWS 最新收录文献
-
1. Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes, and translational barriers.
1. 用于耐多药结直肠癌癌症的生物活性纳米药物：可作用机制、新出现的颗粒类别和转化障碍PMID:日期:2026-11-01Multidrug resistance (MDR) in colorectal cancer (CRC) arises from interacting tumour-cell, pharmacological and microenvironmental programmes that undermine both drug activity and delivery. Chemotherapy-associated MDR is the principal focus of this review, while resistance to targeted therapy and immunotherapy is considered where it directly affects delivery design or patient selection. Bioactive compounds can modulate several resistance pathways, but their translational value is constrained by poor solubility, instability, rapid metabolism and inadequate exposure at resistant lesions. This review critically examines when nanomedicine can make such mechanistic activity pharmacologically and translationally meaningful. We link resistance biology to delivery functions, evaluate bioactive chemosensitiser candidates against human exposure, compare major nanomedicine design strategies, and assess nano-bio interactions, repeat-dose safety, manufacturing and clinical positioning. Across the evidence, three limitations recur. First, concentrations associated with chemosensitisation for curcumin, resveratrol, epigallocatechin gallate and quercetin generally exceed measured human parent-analyte exposure. Second, many resistance claims rely on parental or poorly characterised models, whereas studies combining defined resistance provenance with functional mechanism and exposure confirmation remain uncommon. Third, human studies demonstrate feasibility, tissue exposure or treatment response, but not mechanism-specific reversal of CRC MDR by a bioactive compound or bioactive nanomedicine. Progress therefore depends less on adding new particle classes than on matching a necessary formulation function to a defined resistance or spatial barrier, quantifying active exposure in the relevant compartment, validating mechanism in appropriate models, and integrating repeat-dose safety, scalable manufacturing and biomarker-guided clinical development.
-
2. Coupling redox regulation with Cancer immunotherapy: The challenge of polyphenol Nanocarriers.
2. 将氧化还原调节与癌症免疫治疗相结合：多酚纳米载体的挑战PMID:日期:2026-11-01Cancer progression is closely associated with dysregulated redox homeostasis within the tumour microenvironment (TME), where reactive oxygen and nitrogen species influence tumour survival, immune evasion, and therapeutic resistance. While physiological redox signalling supports antitumour immunity, persistent oxidative stress promotes immunosuppression and limits the efficacy of immunotherapies, making redox modulation an attractive therapeutic strategy. Naturally occurring polyphenols have emerged as promising redox-regulating agents due to their antioxidant, anti-inflammatory, and immunomodulatory properties. Beyond scavenging reactive species, they regulate pathways involved in immune activation, metabolic reprogramming, ferroptosis, and tumour-immune interactions. However, their clinical application is hindered by poor bioavailability, rapid metabolism, and limited tumour accumulation. Nanotechnology-based delivery systems, including liposomes, polymeric nanoparticles, metal-based nanoplatforms, biomimetic vesicles, and stimuli-responsive carriers, have been developed to overcome these limitations. These platforms enhance polyphenol stability, targeted delivery, and controlled release while enabling synergistic interactions with immunotherapy. Importantly, they can function as programmable redox-immunomodulatory systems capable of remodelling the TME, inducing immunogenic cell death, promoting ferroptosis, and activating innate and adaptive immune responses. This review discusses the interplay between redox regulation and tumour immunity, examines the immunomodulatory mechanisms of polyphenols, and highlights recent advances in nanocarrier-based delivery strategies. Challenges related to biological heterogeneity, biomarker development, manufacturing scalability, regulatory approval, and clinical translation are also considered, together with future perspectives for precision redox medicine based on polyphenol-enabled nanotechnologies.
-
3. From PEG to randomized PEG: a macromolecular strategy tackling PEG immunogenicity.
PMID:日期:2026-11-01PEGylation is a crucial strategy in modern nanomedicine, offering effective and safer therapeutics. However, the growing prevalence of anti-PEG antibodies (APAs) in patients has raised critical concerns, with multiple studies demonstrating reduced clinical efficacy and safety risks associated with APA formation. This has generated broad consensus on the need for next-generation nanomedicine solutions, leading to the development of several promising alternatives to PEG. However, antibodies against some alternatives have already been reported. Furthermore, full understanding of PEG immunogenicity and clinical impact is highly relevant before switching to another polymeric structure. Therefore, a detailed consideration of immunogenicity and molecular recognition patterns is recommended to guide the next generation of nanomedicine. To address these challenges, the randomized PEG (rPEG) technology has recently been introduced, capitalizing on APA structure knowledge. The random incorporation of "synthetic point mutations", i.e., glycidyl methyl ether, disrupts the regularity of PEG, while preserving the polyether key properties. Reduced antigenicity of rPEG was confirmed via ELISA, MST, and FCS analysis. Further in vitro studies demonstrated that rPEG is noncytotoxic, does not interact with blood, and is unlikely to activate complement. In nanoparticle applications, rPEG-based polymeric micelles and lipid nanoparticles exhibited reduced antigenicity and comparable mRNA transfection efficiency to their PEGylated counterparts, respectively. Recent in vivo studies demonstrated that rPEG-liposomes, across a series of PEG alternatives, were the only formulations that did not exhibit accelerated blood clearance, even following cross-immunization with PEGylated liposomes. Although stealth performance requires further optimization, rPEG represents a highly promising PEG alternative.
-
4. Redox-responsive nanomaterials for mRNA delivery: From rational design to therapeutic applications.
PMID:日期:2026-11-01Messenger RNA (mRNA) therapeutics have emerged as a transformative biomedical platform with broad potential in vaccination, protein replacement, gene editing, and cancer immunotherapy. Despite substantial progress, the broader clinical translation of mRNA therapeutics requires further optimization of delivery systems to address challenges related to stability, biodistribution, intracellular delivery efficiency, and biosafety. In this review, we discuss the rational design of redox-responsive nanomaterials that exploit physiological intracellular redox compartmentalization or, in selected systems, disease-associated oxidative or reductive dysregulation to improve mRNA delivery. We first summarize the biological basis of redox-responsive delivery by linking disease-associated redox imbalance with the engineering principles of responsive nanomaterials. We then systematically discuss major classes of redox-responsive systems, including oxidation-responsive, reduction-responsive, and dual-responsive platforms across polymeric, lipid-based, and hybrid nanomaterial formulations. Particular emphasis is placed on how distinct chemical architectures and responsive motifs influence intracellular delivery behavior, cargo release, immune compatibility, and therapeutic performance. Finally, we discuss current translational challenges, including long-term biosafety, repeated administration, immunogenicity, and large-scale manufacturing, while highlighting emerging opportunities such as AI-assisted material design and personalized theranostic applications. Collectively, this review provides a comprehensive framework for understanding how redox-responsive nanomaterial engineering may advance the next generation of precise and clinically translatable mRNA therapeutics.
-
5. The landscape of genetic medicines for in vivo T cell reprogramming.
PMID:日期:2026-11-01In vivo reprogramming of T cells represents a transformative approach in immune-based therapies, with the potential to overcome the limitations of traditional ex vivo-engineered T cell products, such as autologous CAR-T therapies. While CAR-T cells have achieved remarkable success in treating hematological cancers with several FDA-approved products, challenges like manufacturing complexity, costs, toxicity, and relapse rates persist. In this review, we first provide a brief background on T cell biology and CAR T cells, and then present a comprehensive overview of emerging strategies for direct in vivo T cell reprogramming. We discuss the key platform technologies, including lipid nanoparticles and viral vectors, and the targeting methods employed to enhance delivery and efficacy. Moreover, we evaluate the functional state of reprogrammed T cells and the role of different mouse models and reporter systems in assessing their therapeutic potential. We highlight key challenges related to the biodistribution, activation, and persistence of modified T cells, with an emphasis on the potential of these strategies for treating not only blood cancers but also solid tumors, autoimmune diseases, and beyond. Finally, we provide an outlook on future directions by highlighting recent non-human primate studies, ongoing clinical activities, and strategic acquisitions representing key innovations, and discuss remaining translational hurdles in the field.
-
6. Intranasal drug delivery to the brain for neurodegenerative diseases: Current efforts and challenges in delivery platforms and modeling.
6. 神经退行性疾病的鼻内药物递送至大脑：递送平台和建模方面的当前努力和挑战PMID:日期:2026-11-01Neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD), globally pose a significant challenge with an aging population. Despite the presence of various therapeutic agents, AD and PD treatments with small molecules currently only address the symptoms; certain biologic agents for AD have been approved for their disease-modifying effects, but the risk of intracerebral hemorrhage severely limits their use. Moreover, the bioavailability of orally administered agents in the brain is challenged by the blood-brain barrier, complicating brain-targeted drug development. Extensive efforts are currently underway to develop intranasal platforms with nanoparticles for direct nose-to-brain drug delivery. Additionally, various in vitro designs involving brain organoids, and in vivo models, such as rodents and zebrafish, have been explored to improve the efficiency and accuracy of preclinical models. Efforts to develop sophisticated computational modeling of intranasal drug delivery, including computational fluid dynamics (CFD) deposition and physiologically based pharmacokinetics (PBPK) modeling, also continue to advance the intranasal drug delivery research and potentially improve the feasibility of developing clinically relevant intranasal platforms for neurodegenerative disease.
-
7. Decoding cellular dynamics and microenvironmental responses in organ-on-chip systems through real-time sensing.
7. 通过实时传感解码器官芯片系统中的细胞动力学和微环境反应PMID:日期:2026-10-01Organ-on-Chip (OoC) systems hold extraordinary promise for predictive drug development and disease modeling. Yet, their translational impact is constrained by several challenges, one of which is the inability to monitor cellular microenvironments and tissue behavior in real time, without destructive sampling. In the absence of real-time sensing capabilities, OoC characterization often relies on intermittent or endpoint measurements, where inputs and endpoints are known, but transient cellular mechanisms driving biological responses remain elusive. This ambiguity limits mechanistic insights and complicates model validation essential for pre-clinical decision-making. Integrating sensing capabilities into OoCs resolves this gap by enabling continuous, non-invasive monitoring of multi-parametric cellular and microenvironmental dynamics. This review presents an overview of the current state of real-time OoC sensing, examining how electrochemical, optical, affinity-based, and mechanical sensing modalities capture real-time data related to barrier integrity, metabolic shifts, ion dynamics, biomarker secretion, and contractile force. It discusses data from representative organ systems (brain, gut, liver, kidney, etc.), commercially available platforms, and disease-modeling applications, highlighting enhanced predictive potential relative to the conventional pre-clinical models. Innovations in multi-modal sensors and AI/ML-based data analysis are advancing OoCs toward high-throughput drug safety and efficacy assessments. However, persistent challenges such as sensor miniaturization, lack of standardized calibration protocols, batch-to-batch reproducibility, signal interference in complex media, economic barriers, and lack of binding international regulatory guidelines impede scalable translation. Addressing these gaps through co-ordinated standardization, regulatory harmonization, and infrastructure development is essential to unlock OoCs as routine pre-clinical tools capable of reducing animal use, accelerating therapeutic translation, and improving patient outcomes.
-
8. Redox-activated heavy-atom-free photosensitizers for enhanced photodynamic cancer therapy.
PMID:日期:2026-10-01In recent years, heavy-atom-free photosensitizers have been recognized as an important class of agents for photodynamic therapy (PDT). In particular, redox-activated heavy-atom-free photosensitizers inspired by the redox imbalance of the tumor microenvironment are emerging as a promising strategy to improve the specificity and therapeutic efficiency of PDT. This review highlights design strategies of redox-activated heavy-atom-free photosensitizers (PSs), including donor-acceptor-based frameworks, thionation, aggregation-induced emission (AIE) driven intersystem crossing enhancement, and the integration of responsive moieties for reactive oxygen species (ROS), glutathione (GSH), cysteine (Cys), and hydrogen sulfide (H₂S). In addition, recent advances in the development of redox-activated heavy-atom-free PSs over the past three years are summarized. Finally, main challenges, including hypoxic tumors, limited tumor-targeting efficiency, and limited light penetration into deep-seated tumors, as well as future prospects for this field, are discussed.
-
9. Enabling formulations for PROTACs: A line-of-sight to clinic.
PMID:日期:2026-10-01Proteolysis targeting chimeras (PROTACs) occupy a challenging oral developability space defined by high molecular weight, elevated polarity and lipophilicity, and substantial conformational flexibility, placing many candidates beyond conventional oral drug-likeness criteria and frequently within Biopharmaceutics Classification System (BCS) class II or IV. These properties create modality-specific constraints in solid-state behaviour, solubility and supersaturation, permeability, and intestinal transport, which together can limit oral absorption and contribute to variable systemic exposure. Many PROTACs exhibit low aqueous and biorelevant solubility, inconsistent maintenance of supersaturation, and uncertain effective permeability complicated by non-specific binding, efflux, and assay-related artefacts, thereby hindering early developability assessment and physiologically based biopharmaceutics modelling (PBBM). To support phase-appropriate development, we propose an early, flexible quality target product profile (eQTPP) framework to guide formulation selection, define evidence requirements for progression, and inform clinical bridging strategy. Within this context, the review evaluates clinically deployable enabling formulation strategies. Solubilisation approaches based on co-solvents, surfactants, and cyclodextrins can increase dissolved concentrations, although their utility is often limited by precipitation on dilution and poor translation to oral solid dosage forms. Lipid-based formulations, including self-emulsifying and supersaturated systems, align with the high lipophilicity of many PROTACs and can improve solubilisation and, in selected cases, permeability or lymphatic access, but may introduce challenges in drug loading, capsule compatibility, and fill stability. Amorphous solid dispersions offer a versatile approach to enhancing dissolution and sustaining supersaturation with favourable manufacturability potential, although polymer-bile interactions and species-dependent effects can generate in vitro-in vivo disconnects. Permeation enhancement remains a secondary strategy constrained by safety, dose, and formulation complexity. The review then considers clinical translation, including fed/fasted state, acid-reducing agent effects, and PBBM-informed bridging, before briefly highlighting future opportunities for local delivery. We therefore propose pragmatic decision frameworks integrating physicochemical characterisation, biorelevant testing, and PBBM to support formulation selection and translation. Overall, successful oral PROTAC development depends on selecting the simplest phase-appropriate enabling strategy that addresses the dominant absorption bottleneck while minimising development risk.
-
10. Redox-responsive LNPs for therapeutics delivery.
10. 用于治疗递送的氧化还原反应性LNPsPMID:日期:2026-10-01Redox-responsive lipid nanoparticles (LNPs) are emerging as a powerful platform for precision nanomedicine by exploiting disease-associated redox imbalances, such as elevated glutathione and reactive oxygen species, to trigger controlled cargo release and structural activation. This strategy is of great importance for developing gene-based therapeutics, where efficient cytosolic delivery is essential. In addition to nucleic acids, redox-responsive LNPs have also been explored in delivering small molecules, proteins, and theranostic agents, broadening their potential in both cancer and non-cancer diseases. This review summarizes the biological basis of redox responsiveness, key design principles for responsive chemical structures, and major advances in payload delivery and targeting capability of LNP carriers. Moreover, some major bottlenecks, including redox heterogeneity, stability, responsiveness trade-offs, and translational complexity, are critically discussed. Future directions are also highlighted, particularly for organ-selective delivery, multifunctional theranostics, and clinically translatable LNP-based medicines.